• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600866.SS
Share

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong Stocks

CN¥ 5.31Last Updated 26.05.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 1.29B

CN¥ 5.31
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Star Lake Bioscience Co., Inc. manufactures and sells pharmaceutical raw materials, and food and feed additives in China and internationally. The company offers guanosine that is used as an intermediate for food and pharmaceutical raw material; L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; adefovir dipivoxil tablets used to reduce the activity of HBV DNA polymerase and anti-virus by destroying Hepatitis B virus DNA; and L-threonine that is used in premixtures, and pig and poultry feed. It also provides disodium 5'-ribonucleotide to cure chronic hepatitis, muscular atrophy, and eye diseases; disodium 5-inosinate to cure leukopenia, thrombocytopenia, and chronic and acute hepatitis; and inosine, which is used for the treatment of chronic hepatitis, heart disease, leukopenia or thrombocytopenia, central choroidoretinitis, etc. In addition, the company offers disodium 5'-guanylate for canned meat, ham, salted meat, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc. The company offers its products under the Star Lake and Yue Bao brands. Star Lake Bioscience Co., Inc. was founded in 1964 and is based in Zhaoqing, China.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, undervalue

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 13:45

Rallying 35%: report and Amazon partnership revive interest in Snowflake stock

28.05.2026 12:53

Meta has started selling AI subscriptions to chatbot and social networks. The shares jumped by 4%

28.05.2026 12:24

Boeing called China's order for 200 airplanes the "first tranche." The market was disappointed with it

28.05.2026 11:00

Oil jumped 4% after the exchange of blows between the U.S. and Iran. What's in the markets?

28.05.2026 10:19

Top stories for the morning: oil rises on US and Iran strikes, Dell gets Pentagon contract

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026